Danish pharmaceutical company Novo Nordisk A/S (NOVO-B.KO) Wednesday raised its financial guidance for 2010 and said it expects continued growth in 2011, as it posted a rise in third-quarter earnings, driven by strong sales of diabetes treatments.

Novo Nordisk said it now expects 2010 sales growth of 11%-12% and operating profit growth of more than 15% in local currencies compared with 2009. It previously expected sales growth of 9%-10% and operating profit growth of 12%-15% in local currencies.

The "preliminary plans" for 2011 indicate sales growth of close to 10% and operating profit growth of 10%-15% in local currencies, it said.

Growth in 2011 will be boosted by strong penetration of modern insulins and continued roll-out of new diabetes treatment Victoza, Novo Nordisk said. But it also predicted generic competition to oral antidiabetic products and negatively impact from healthcare reforms in its markets.

The Copenhagen-based company posted net profit for the three months to Sept. 30 of 3.59 billion Danish kroner ($665 million), up from DKK2.76 billion a year earlier and slightly ahead of analysts' expectations for DKK3.36 billion.

"Growth was driven by the modern insulins, Victoza and NovoSeven," the company said.

Novo Nordisk said its drug candidate Degludec showed good blood sugar control in a recent study where it was compared with diabetes treatment NovoMix.

Investors have big hopes for the drug candidate, which according to earlier studies controls blood sugar in a stable and predictable way, and might boost earnings following a planned launch in 2013.

It also said new study data for Victoza indicates that the drug can effectively help obese people lose weight.

Third-quarter sales rose 25% to DKK15.58 billion, ahead of expectations for DKK14.79 billion. Operating profit rose to DKK5.12 billion from DKK3.81 billion, beating expectations for DKK4.74 billion.

Due to the rapid spread of diabetes, Novo Nordisk's earnings have grown steadily, driven by rising sales of treatments for the disease like insulins as well as the recently-launched Victoza, which belongs to the GLP-1 analogue drug class and compared with insulin doesn't risk pushing blood sugar too low.

That drug looks set to gain a strong position in its market segment after U.S. regulators last week demanded additional studies before approving the rival treatment Bydureon from Eli Lilly & Co (LLY), Amylin Pharmaceuticals Inc. (AMLN) and Alkermes Inc. (ALKS).

Victoza generated sales of DKK700 million in the third quarter, up from DKK28 million a year earlier.

Still, market participants say Novo Nordisk faces rising generic competition over coming years.

Its shares were hit earlier this month after drug maker Pfizer Inc (PFE) bought the rights to commercialize a set of biosimilar diabetes treatments--similar but not identical versions of existing drugs--from India's Biocon Ltd. (532523.BY).

Victoza was the main driver of the strong result, said analyst Michael Friis Jorgensen at Alm. Brand, adding that the positive study results for the drug and for Degludec could bode well for future earnings.

The raised 2010 guidance just confirms the market's bullish expectations, but the preliminary outlook for 2011 was surprisingly strong, he said.

At 0742 GMT, shares in Novo Nordisk were up 1.2% at DKK545.50, against a 0.3% rise in the wider Copenhagen market.

-By Gustav Sandstrom, Dow Jones Newswires; +46-8-5451-3099; gustav.sandstrom@dowjones.com
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Amylin Pharmaceuticals, Inc. (MM) Charts.
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Amylin Pharmaceuticals, Inc. (MM) Charts.